Table 2.

Estimated relative lifetime number of ovulatory cycles and ovarian cancer risk or likelihood of anti-MUC1 antibodies

Lifetime no. ovulatory cycles*Association with ovarian cancer
Association with anti-MUC1 antibodies
Cases, n (%)Controls, n (%)OR (95% CI)P trendNegative, n (%)Positive, n (%)OR (95% CI)P trend
≤45
    Low44 (39)68 (61)1.000.00138 (56)30 (44)1.000.99
    Medium44 (39)69 (61)1.15 (0.65-2.05)42 (64)24 (36)0.91 (0.41-2.01)
    High91 (56)71 (44)2.97 (1.53-5.75)41 (60)27 (40)0.99 (0.38-2.64)
46-60
    Low62 (39)95 (61)1.000.00157 (61)37 (40)1.000.04
    Medium83 (46)96 (54)1.38 (0.89-2.15)65 (71)27 (29)0.62 (0.33-1.18)
    High115 (55)94 (45)2.10 (1.35-3.29)68 (74)24 (26)0.49 (0.25-0.97)
>60
    Low39 (39)60 (61)1.000.0641 (68)19 (32)1.000.76
    Medium55 (48)59 (59)1.41 (0.81-2.46)39 (67)19 (33)1.12 (0.51-2.47)
    High68 (52)62 (62)1.70 (0.99-2.93)44 (72)17 (28)0.88 (0.40-1.96)
All ages
    Low145 (39)223 (61)1.00<0.0001136 (61)86 (38)1.000.06
    Medium182 (45)224 (55)1.25 (0.94-1.67)146 (67)70 (32)0.76 (0.51-1.13)
    High274 (55)227 (45)1.88 (1.42-2.47)153 (69)68 (30)0.68 (0.45-1.03)
  • * There are 114 women missing estimated lifetime number of ovulatory cycles because they reported that their menstrual cycles were never regular.

  • Adjusted for reference age (continuous), study center (Massachusetts or New Hampshire), cesarean section, tubal ligation, and hysterectomy.

  • The ≤45 group was not adjusted for hysterectomy because only one woman was MUC1 positive with a hysterectomy, so estimate was unstable.